Your browser doesn't support javascript.
loading
Development of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting.
Pawar, Atmaram; Singh, Srishti; Rajalakshmi, S; Shaikh, Karimunnisa; Bothiraja, C.
Afiliação
  • Pawar A; a Department of Pharmaceutics , Poona College of Pharmacy, Bharati Vidyapeeth Deemed University , Pune , India.
  • Singh S; a Department of Pharmaceutics , Poona College of Pharmacy, Bharati Vidyapeeth Deemed University , Pune , India.
  • Rajalakshmi S; b Department of Pharmaceutics , Dr. D. Y. Patil College of Pharmacy , Pune , India.
  • Shaikh K; c Department of Pharmaceutics , Modern College of Pharmacy , Pune , India.
  • Bothiraja C; a Department of Pharmaceutics , Poona College of Pharmacy, Bharati Vidyapeeth Deemed University , Pune , India.
Artif Cells Nanomed Biotechnol ; 46(sup1): 347-361, 2018.
Article em En | MEDLINE | ID: mdl-29334247
ABSTRACT
The natural flavonoid fisetin (FS) has shown anticancer properties but its in-vivo administration remains challenging due to its poor aqueous solubility. The aim of the study was to develop FS loaded pluronic127 (PF)-folic acid (FA) conjugated micelles (FS-PF-FA) by the way of increasing solubility, bioavailability and active targetability of FS shall increase its therapeutic efficacy. FA-conjugated PF was prepared by carbodiimide crosslinker chemistry. FS-PF-FA micelles were prepared by thin-film hydration method and evaluated in comparison with free FS and FS loaded PF micelles (FS-PF). The smooth surfaces with spherical in shape of FS-PF-PF micelles displayed smaller in size (103.2 ± 6.1 nm), good encapsulation efficiency (82.50 ± 1.78%), zeta potential (-26.7 ± 0.44 mV) and sustained FS release. Bioavailability of FS from FS-PF-PF micelles was increased by 6-fold with long circulation time, slower plasma elimination and no sign of tissue toxicity as compared to free FS. Further, the FS-PF-FA micelles demonstrated active targeting effect on folate overexpressed human breast cancer MCF-7 cells. The concentration of the drug needed for growth inhibition of 50% of cells in a designed time period (GI50) was 14.3 ± 1.2 µg/ml for FS while it was greatly decreased to 9.8 ± 0.78 µg/ml, i.e. a 31.46% decrease for the FS-PF. Furthermore, the GI50 value for FS-PF-FA was 4.9 ± 0.4 µg/ml, i.e. a 65.737% decrease compared to FS and 50% decrease compare to FS-PF. The results indicate that the FS-PF-FA micelles have the potential to be applied for targeting anticancer drug delivery.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Flavonoides / Neoplasias da Mama / Portadores de Fármacos / Poloxâmero / Ácido Fólico / Micelas Limite: Animals / Humans Idioma: En Revista: Artif Cells Nanomed Biotechnol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Flavonoides / Neoplasias da Mama / Portadores de Fármacos / Poloxâmero / Ácido Fólico / Micelas Limite: Animals / Humans Idioma: En Revista: Artif Cells Nanomed Biotechnol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Índia